Key oncology medicines (relevant to imports/usage patterns in China, Kazakhstan, and Russia).

1. Pembrolizumab (PD-1 inhibitor immunotherapy)

  • Originator Brand: Keytruda (Merck)
  • Common Pack: 100 mg / 4 mL single-dose vial (injection)
  • Biosimilars in India: Emerging/approved (e.g., collaborations like Dr. Reddy’s with Alvotech for pembrolizumab biosimilar)
  • Manufacturer: Merck Sharp & Dohme (originator)
  • Typical Use: Lung cancer, melanoma, head & neck, etc. (Cost: ~₹1.5–2 lakh per 100 mg vial)

2. Nivolumab (PD-1 inhibitor)

  • Originator Brand: Opdivo (Bristol Myers Squibb)
  • Common Pack: 40 mg/4 mL or 100 mg/10 mL vial
  • Biosimilars in India: Available/limited biosimilar options
  • Manufacturer: BMS (originator)
  • Typical Use: Lung, kidney, melanoma, etc.

3. Osimertinib (EGFR TKI)

  • Originator Brand: Tagrisso (AstraZeneca)
  • Common Pack: 40 mg or 80 mg tablets (blister of 30 tablets)
  • Biosimilars in India: Limited (mainly originator; some generics in pipeline)
  • Manufacturer: AstraZeneca
  • Typical Use: Non-small cell lung cancer (Cost: ~₹1–2 lakh per month)

4. Trastuzumab (HER2 monoclonal antibody)

  • Originator Brand: Herceptin (Roche)
  • Common Pack: 440 mg vial (lyophilized powder for injection)
  • Biosimilars in India: Hervycta (Biocon), Canmab (Biocon), others from Dr. Reddy’s/Intas
  • Manufacturer: Roche (originator); Biocon, Dr. Reddy’s, etc. (biosimilars)
  • Typical Use: HER2+ breast/gastric cancer (Biosimilar price: ~₹20,000–60,000 per 440 mg)

5. Rituximab (CD20 monoclonal antibody)

  • Originator Brand: MabThera / Rituxan (Roche)
  • Common Pack: 100 mg/10 mL or 500 mg/50 mL vial
  • Biosimilars in India: Reditux (Dr. Reddy’s), Ristova, others
  • Manufacturer: Roche (originator); Dr. Reddy’s, Biocon, etc. (biosimilars)
  • Typical Use: Lymphoma, leukemia (Biosimilar: ~₹8,000–30,000 per vial)

6. Bevacizumab (VEGF inhibitor)

  • Originator Brand: Avastin (Roche)
  • Common Pack: 100 mg/4 mL or 400 mg/16 mL vial
  • Biosimilars in India: Versavo (Dr. Reddy’s), others
  • Manufacturer: Roche (originator); Dr. Reddy’s, etc. (biosimilars)
  • Typical Use: Colorectal, lung, ovarian cancers

7. Cisplatin (Platinum-based chemotherapy)

  • Originator / Common Brands: Various (e.g., Platinol historically; current generics like Kemoplat, Cisplam)
  • Common Pack: 10 mg/20 mL, 50 mg/50 mL, or 100 mg vial (injection)
  • Biosimilars / Generics in India: Widely available as generics (no distinct “originator” premium now)
  • Manufacturer: Cipla, Fresenius Kabi, Intas, Dr. Reddy’s, etc.
  • Typical Use: Broad spectrum cancers (lung, ovarian, testicular) – highly affordable

Additional Common Options in India

  • Imatinib (for CML/GIST): Veenat (Natco), Imatib (Cipla) – 100/400 mg tablets. Generics widely available.
  • Paclitaxel / Docetaxel: Multiple generics (e.g., Taxol by BMS origin, many Indian makers) – 30/100/260 mg vials.

Key Indian Manufacturers for these and other oncology drugs: Dr. Reddy’s Laboratories, Biocon, Natco Pharma, Cipla, Sun Pharma, Intas, Zydus, Emcure, and others.

Important Notes:

  • Biosimilars offer significant cost savings while maintaining similar efficacy and are widely used in India.
Print Friendly, PDF & Email